MX2020008413A - Composiciones para la prevencion o tratamiento de la uveitis. - Google Patents

Composiciones para la prevencion o tratamiento de la uveitis.

Info

Publication number
MX2020008413A
MX2020008413A MX2020008413A MX2020008413A MX2020008413A MX 2020008413 A MX2020008413 A MX 2020008413A MX 2020008413 A MX2020008413 A MX 2020008413A MX 2020008413 A MX2020008413 A MX 2020008413A MX 2020008413 A MX2020008413 A MX 2020008413A
Authority
MX
Mexico
Prior art keywords
preventing
treating uveitis
compositions
compound
pharmaceutical composition
Prior art date
Application number
MX2020008413A
Other languages
English (en)
Inventor
Nina Ha
Young Il Choi
Taek Hwan Shin
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of MX2020008413A publication Critical patent/MX2020008413A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para la prevención o el tratamiento de la uveítis, que contiene un compuesto representado por una fórmula I, un isómero óptico del mismo o una sal farmacéuticamente aceptable del mismo, como un componente eficaz, así como a un método de tratamiento que usa el compuesto y al uso del compuesto en la fabricación de un medicamento para el tratamiento de la uveítis. La composición farmacéutica de acuerdo con la presente invención muestra un efecto excelente para la prevención o el tratamiento de la uveítis.
MX2020008413A 2018-02-20 2019-02-19 Composiciones para la prevencion o tratamiento de la uveitis. MX2020008413A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180020058A KR20190099952A (ko) 2018-02-20 2018-02-20 포도막염의 예방 또는 치료를 위한 조성물
PCT/KR2019/001989 WO2019164222A1 (en) 2018-02-20 2019-02-19 Compositions for preventing or treating uveitis

Publications (1)

Publication Number Publication Date
MX2020008413A true MX2020008413A (es) 2020-09-25

Family

ID=67686848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008413A MX2020008413A (es) 2018-02-20 2019-02-19 Composiciones para la prevencion o tratamiento de la uveitis.

Country Status (12)

Country Link
US (1) US20210077501A1 (es)
EP (1) EP3755336A4 (es)
JP (1) JP7058745B2 (es)
KR (1) KR20190099952A (es)
CN (1) CN111801101A (es)
AU (1) AU2019224697B2 (es)
BR (1) BR112020016333A2 (es)
CA (1) CA3088956A1 (es)
MX (1) MX2020008413A (es)
PH (1) PH12020551117A1 (es)
RU (1) RU2757273C1 (es)
WO (1) WO2019164222A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
KR102236356B1 (ko) 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US792347A (en) * 1904-09-19 1905-06-13 Alonzo H Pence Horse-detacher.
ES2225252T3 (es) * 1999-11-10 2005-03-16 Takeda Chemical Industries, Ltd. Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica.
BR0307631A (pt) * 2002-02-14 2004-12-21 Pharmacia Corp Piridinonas substituìdas como moduladores de p38 map-quinase
US20060074100A1 (en) * 2002-11-12 2006-04-06 Klimko Peter G Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US7923471B2 (en) * 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
WO2007039322A1 (en) * 2005-09-19 2007-04-12 Bioxell Spa Use of vitamin d3 compounds for the treatment of uveitis
MX2012008553A (es) * 2010-01-22 2012-11-30 Acetylon Pharmaceuticals Inc Compuestos de amida inversa como inhibidores de proteina desacetilasa y metodos de uso de los mismos.
CA2818125A1 (en) * 2010-11-16 2012-05-24 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
TW201245115A (en) * 2011-01-24 2012-11-16 Chdi Foundation Inc Histone deacetylase inhibitors and compositions and methods of use thereof
US9218690B2 (en) * 2012-08-29 2015-12-22 Ge Aviation Systems, Llc Method for simulating hyperspectral imagery
RU2634694C2 (ru) 2013-04-29 2017-11-03 Чонг Кун Данг Фармасьютикал Корп. Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения

Also Published As

Publication number Publication date
CA3088956A1 (en) 2019-08-29
US20210077501A1 (en) 2021-03-18
BR112020016333A2 (pt) 2020-12-15
EP3755336A1 (en) 2020-12-30
EP3755336A4 (en) 2021-12-01
KR20190099952A (ko) 2019-08-28
JP7058745B2 (ja) 2022-04-22
JP2021514366A (ja) 2021-06-10
CN111801101A (zh) 2020-10-20
AU2019224697A1 (en) 2020-08-06
PH12020551117A1 (en) 2021-07-05
RU2757273C1 (ru) 2021-10-12
AU2019224697B2 (en) 2021-09-09
WO2019164222A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2021004707A (es) Nuevos compuestos antihelminticos.
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
PH12018500378B1 (en) Novel annelated phenoxyacetamides
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
NZ757711A (en) Antimicrobial compounds, compositions, and uses thereof
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
WO2019207257A8 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
SG10201907289VA (en) Monomethylfumarate prodrug compositions
PH12020551117A1 (en) Compositions for preventing or treating uveitis
SG11201907945YA (en) Azetidine derivative
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
PH12020551620A1 (en) Compositions for preventing or treating dry eye
PH12020550549A1 (en) Compositions for preventing or treating lupus
MX2019011558A (es) Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2022005912A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.